MaidStone Life Science/William Blair Biotech Conference

 

  Day 1

10th Annual Cancer Immunotherapy Conference

10:00 a.m.

Keynote I: Targeting the Tumor Microenvironment

Miriam Merad, M.D., Ph.D.,

Chair Professor in Cancer Immunology

And Director of the Precision Immunology Institute

Mount Sinai School of Medicine

 

Q&A

10: 50 a.m.

Break

11:00 a.m.

to 12:00 p.m.

Targeting Myeloid Cells in Tumor Microenvironment

 

Douglas Williams, Ph.D.

President and Chief Executive Officer

Codiak Biosciences (private)

 

Jennifer Buell, Ph.D.,

Chief Operating Officer

Agenus, Inc. (AGEN)

 

Q&A

 

 

12:10 p.m.

to 12:40 p.m.

A Novel Way to Target Antigen Negative Tumor Cells by Targeting Their Geography

Joshua Brody, M.D.

Director Lymphoma Immunotherapy Program

Icahn School of Medicine at Mount Sinai,

Hess Center for Science and Medicine

 

Q&A

12:40 p.m.

Break

12:50 p.m.

to 2:30 p.m.

 

Direct Anti-Tumor Activity and Influence on Tumor Microenvironment

 

Peter Lamb, Ph.D.

Executive Vice President, Scientific Strategy and Chief Scientific Officer

Exelixis, Inc.

 

Sam Whiting, M.D., Ph.D.

Senior Vice President of Clinical Development

Calithera (CALA)

 

Tom Dubensky, Jr., Ph.D.

Chief Executive Officer

Tempest Therapeutics (private)

2:20 p.m.

Q&A

2:30 p.m.

Break

2:40 p.m.

to 3:55 p.m.

Bispecific Antibodies Direct T-Cell Engagers and Tumor Localized Immune Pathway Modulation

 

John Lin, M.D., Ph.D.

Senior Vice President, Immune Oncology

Head of Bispecific R&D

Regeneron Pharmaceuticals

 

Ingmar Bruns, M.D., Ph.D.

Senior Vice President, Head of Clinical Development

Pieris Pharmaceuticals (PIRS)

 

Q&A

 

 

 

 

Day Two

 

10:00 a.m.

to 11:40 p.m

Engineered NK Cells

10:00 a.m.

Keynote II: NK Cells in Cancer Immunotherapy

Amir Horowitz, PhD

Assistant Professor of Oncological Sciences

Member Precision Immunology Institute

Mount Sinai School of Medicine

10:45 a.m.

Q&A

10:50 a.m.

David Gilham, Ph.D.

Vice President, Research and Development

Celyad (CYAD)

11:10 a.m.

Bob Valamehr, Ph.D.

Chief Development Officer

Fate Therapeutics (FATE)

11:30 a.m.

Q&A

11:40 a.m.

Break

12:00 p.m.

Keynote III: Engineered T-Cell Therapies

Marco Davila, M.D., Ph.D.

Associate Member, Department of Blood and Marrow Transplantation

H. Lee Moffitt Cancer Center and Research Institute

12:35 p.m.

Q&A

 

 

 

12:40 p.m.

to 1:50 p.m

Advancements in Engineered Cell Therapies

 

Michael Leeks, Ph.D., M.B.A.

Chairman, Chief Executive Officer

TC Biopharm Ltd. (Private)

 

Andre Choulika, Ph.D.

Chief Executive Officer

Cellectis (CLLS)

 

 

 

Christian Itin, Ph.D.

Chairman, Chief Executive Officer

Autolus (AUTL)

 

 

1:50 p.m.

Break

2:00 p.m.

to 3:30 p.m.

 

Discovery of Novel TCRs and Making Personalized Therapies

 

 

Alfred Slanetz, Ph.D.

Chief Executive Officer

Geneius Biotech (private)

 

Karin Jooss, Ph.D.

Executive Vice President of Research

Chief Scientific Officer

Gritstone Oncology (GRTS)

 

Sharon Benzino, Ph.D.

Senior Vice President Drug Discovery

Adaptive Biotechnologies (ADPT)

 

Q&A

 

Day Three

Key Topics in Biotech and One-on-One Meetings

9:00 a.m.

to 9:45 a.m.

 

Panel 1: Vaccinating against the COVID-19 pandemic

 

Vaccitech Ltd. (Private)

Tom Evans, M.D., Chief Scientific Officer

Translate Bio, Inc. (TBIO)

Frank DeRossa, Ph.D., Chief Technology Officer

 

9:45 a.m.

Break

10:00 a.m.

to 10:45 a.m.

Panel 2: Reinvigorating the Schizophrenia Treatment Landscape Recent Approvals and Novel Mechanisms

 

Cadent Therapeutics, Inc. (Private)

Tim Piser, Ph.D., Chief Scientific Officer

 

Intra-Cellular Therapies, Inc. (ITCI)

Sharon Mates, Ph.D., Chief Executive Officer

 

Karuna Therapeutics, Inc. (KRTX)

Steve Paul, M.D., Chief Executive Officer

 

Fireside Chat - Assembly Biosciences, Inc. (ASMB)

John McHutchison, Chief Executive Officer

 

Fireside Chat - NuCana plc (NCNA)

Hugh Griffith, Chief Executive Officer

Don Munoz, Chief Financial Officer

 

Fireside Chat - Lyra Therapeutics, Inc. (LYRA)

 

Maria Palasis, President and Chief Executive Officer

Don Elsey, Chief Financial Officer

Corinne Noyes, SVP, Commercial Strategy & Market Development

 

 

11:00 a.m.

to 11:45 a.m.

Panel 3: Emerging Therapeutic Approaches in Modulating Pathogenic Fibrogenesis

 

Surrozen, Inc. (Private)

Craig Parker, M.B.A., Chief Executive Officer

Galecto, Inc. (Private)

Hans T. Schambye, M.D., Ph.D., Chief Executive Officer

Blade Therapeutics, Inc. (Private)

Wendye Robbins, M.D., President, Chief Executive Officer

 

Fireside Chat - Allakos Inc. (ALLK)

 

Robert Alexander, Chief Executive Officer

Adam Tomasi, President and Chief Operating Officer

Leo Redmond, Chief Financial Officer

 

Fireside Chat - Krystal Biotech, Inc. (KRYS)

 

Krish Krishnan, Chief Executive Officer

 

Fireside Chat - Axsome Therapeutics, Inc. (AXSM)

 

Herriot Tabuteau, Chief Executive Officer

Mark Jacobson, Chief Operating Officer

 

 

 

 

12:00 p.m.

to 12:45 p.m.

Panel 4: New Therapies Impacting the Epilepsy Treatment Landscape

Jacqueline French, M.D., Professor

NYU Comprehensive Epilepsy Center

 

Xenon Pharmaceuticals Inc. (XENE)

Simon Pimstone, MBChB, Ph.D., FRCPC, Chief Executive Officer

Ovid Therapeutics Inc. (OVID)

Amit Rakhit, M.D., M.B.A., President, Chief Medical Officer

 

Fireside Chat - Precision Biosciences, Inc. (DTIL)

Matt Kane, Chief Executive Officer

 

 

 

 

 

12:45 p.m.

Break

1:00 p.m.

to 1:45 p.m.

Panel 5: Gene Editing, Gene Therapy, and Cell Therapy in 2030

 

Beam Therapeutics, Inc. (BEAM)

John Evans, M.S., M.B.A., Chief Executive Officer

 

CRISPR Therapeutics

Samarth Kulkarni, Ph.D. Chief Executive Officer

 

Selecta Biosciences, Inc. (SELB)

Carsten Brunn, Ph.D., President, Chief Executive Officer

 

Locana, Inc. (Private)

Jim Burns, Ph.D., Chief Executive Officer

 

Fireside Chat - Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

 

Vlad Coric, Chief Executive Officer

Jim Engelhart, Chief Financial Officer

 

Fireside Chat - Nimbus Therapeutics LLC (Private)

 

Annie Chen, M.D., M.P.H., Chief Medical Officer

Jeb Keiper, Chief Executive Officer

 

Fireside Chat - Neurocrine Biosciences (NBIX)

 

Matt Abernethy, Chief Financial Officer

 

1:45 p.m.

Break

2:00 p.m.

to 2:45 p.m

Panel 6: 30 Years of RNA-Targeted Therapies - Where Are We Now?

Triplet Therapeutics (Private)

Nessan Bermingham, Ph.D., Chief Executive Officer

 

Silence Therapeutics plc (SLNCF)

Giles Campion, M.D., Chief Medical Officer

 

Dynacure SAS (Private)

Belinda Cowling, Ph.D., Chief Scientific Officer

 

Ionis Pharmaceuticals, Inc. (IONS)

 

Fireside Chat - Asklepios BioPharmaceutical, Inc. (Private)

 

Sheila Mikhail, CEO and Co-Founder

 

Fireside Chat - PhaseBio Pharmaceuticals, Inc. (PHAS)

 

Jonathan Mow, Chief Executive Officer

John Sharp, Chief Financial Officer

 

Fireside Chat - Albireo Pharma, Inc. (ALBO)

 

Ron Cooper, President and Chief Executive Officer

Simon Harford, Chief Financial Officer

 

Break

 

Panel 7: Advancements in Renal Diseases

 

Kezar Life Sciences, Inc. (KZR)

Noreen Roth Henig, M.D., Chief Medical Officer

 

Chinook Therapeutics, Inc. (Private)

Eric Dobmeier, J.D., Chief Executive Officer

 

Goldfinch Bio, Inc. (Private)

Anthony Johnson, M.D., Chief Executive Officer

 

Retrophin, Inc. (RTRX)

Eric Dube, Ph.D., President, Chief Executive Officer

 

Fireside Chat - Global Blood Therapeutics Inc (GBT)

 

Jeffrey Farrow, Chief

 

Fireside Chat - Vedanta Biosciences, Inc. (Private)

Bernat Olle, Chief Executive Officer